疫苗
目前已有人提出用衣原体疫苗进行治疗的策略,即增强对沙眼衣原体的免疫应答,尤其是 1 型辅助性 T 淋巴细胞(Th1 细胞)应答。已有人提出选择衣原体蛋白作为亚单位疫苗候选株,这些蛋白包括结构蛋白、膜蛋白和分泌蛋白(例如主要外膜蛋白)。[38]Pal S, Peterson EM, Rappuoli R, et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2006;24:766-775.http://www.ncbi.nlm.nih.gov/pubmed/16199110?tool=bestpractice.com[39]Singh SR, Hulett K, Pillai SR, et al. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine. 2006;24:1213-1224.http://www.ncbi.nlm.nih.gov/pubmed/16194585?tool=bestpractice.com 然而,有效的载体或佐剂尚未得到证实。同样地,针对性病性淋巴肉芽肿血清型以及其他沙眼衣原体感染表现的疫苗的有效性仍有待研究。[40]Igietseme JU, Black CM, Caldwell HD. Chlamydial vaccines, strategies and status. Biodrugs. 2002;16:19-35.http://www.ncbi.nlm.nih.gov/pubmed/11908999?tool=bestpractice.com